Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

317.20 

-3.30 -1.0%

as of May 12 '21

52 Week Range:

157.39 349.13


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 12.18
11.04
12.46
13.81
14.16
15.08
18.33
21.55
25.99
31.31
38.12
growth rate -9.4% 12.9% 10.8% 2.5% 6.5% 21.6% 17.6% 20.6% 20.5% 21.8%
Earnings BIT -334.08
132.66
129.75
138.33
191.86
230.06
273.13
313.06
331.38
351.15
432.73
growth rate 100.0% -2.2% 6.6% 38.7% 19.9% 18.7% 14.6% 5.9% 6.0% 23.2%
Avg.PE -6.60
12.20
17.86
24.69
28.60
23.42
27.43
24.87
30.48
29.65
40.22
growth rate 100.0% 46.4% 38.2% 15.8% -18.1% 17.1% -9.3% 22.6% -2.7% 35.7%
ROA -17.10
6.66
6.19
6.37
7.18
7.55
6.48
4.37
6.67
5.90
7.15
growth rate 100.0% -7.1% 2.9% 12.7% 5.2% -14.2% -32.6% 52.6% -11.5% 21.2%
ROE -32.64
18.07
17.28
16.56
19.30
21.25
19.72
13.11
19.16
17.07
19.43
growth rate 100.0% -4.4% -4.2% 16.6% 10.1% -7.2% -33.5% 46.2% -10.9% 13.8%
ROIC -19.32
11.05
9.80
9.19
9.77
10.52
9.45
6.61
10.71
9.08
10.95
growth rate 100.0% -11.3% -6.2% 6.3% 7.7% -10.2% -30.1% 62.0% -15.2% 20.6%
Cur. Ratio 2.13
1.96
1.42
2.24
2.05
1.79
1.52
1.78
1.61
1.44
1.43
growth rate -8.0% -27.6% 57.8% -8.5% -12.7% -15.1% 17.1% -9.6% -10.6% -0.7%
Quick Ratio 1.47
1.20
0.93
1.57
1.46
1.31
1.13
1.34
1.20
1.06
1.01
growth rate -18.4% -22.5% 68.8% -7.0% -10.3% -13.7% 18.6% -10.5% -11.7% -4.7%
Leverage 2.52
2.96
2.64
2.57
2.80
2.82
3.24
2.80
2.93
2.87
2.60
growth rate 17.5% -10.8% -2.7% 9.0% 0.7% 14.9% -13.6% 4.6% -2.1% -9.4%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 165.90
184.81
203.00
220.63
257.99
270.07
364.05
430.02
472.25
514.03
growth rate 11.4% 9.8% 8.7% 16.9% 4.7% 34.8% 18.1% 9.8% 8.9%
Acct.Payable 130.31
123.38
146.94
33.82
36.68
68.49
77.84
66.25
111.50
growth rate -5.3% 19.1% -77.0% 8.5% 86.7% 13.7% -14.9% 68.3%
Cur.Assets 552.90
425.84
485.25
552.55
579.25
559.23
656.83
826.63
897.84
1,021.33
1,201.13
growth rate -23.0% 14.0% 13.9% 4.8% -3.5% 17.5% 25.9% 8.6% 13.8% 17.6%
Total Assets 1,733.40
1,558.32
1,586.34
1,632.76
1,870.58
2,068.50
2,711.80
2,929.92
3,855.88
4,692.79
5,490.83
growth rate -10.1% 1.8% 2.9% 14.6% 10.6% 31.1% 8.0% 31.6% 21.7% 17.0%
Cash 179.20
68.91
109.69
155.93
160.02
117.95
117.63
163.79
195.44
238.01
growth rate -61.6% 59.2% 42.2% 2.6% -26.3% -0.3% 39.3% 19.3% 21.8%
Inventory 100.30
92.97
88.47
89.40
89.04
93.74
95.83
114.96
127.89
160.66
185.70
growth rate -7.3% -4.8% 1.1% -0.4% 5.3% 2.2% 20.0% 11.3% 25.6% 15.6%
Cur.Liabilities 259.80
216.80
342.25
247.03
294.69
311.76
429.59
463.50
558.22
710.18
839.75
growth rate -16.6% 57.9% -27.8% 19.3% 5.8% 37.8% 7.9% 20.4% 27.2% 18.2%
Liabilities 1,046.00
1,032.74
985.54
971.19
1,166.23
1,302.93
1,858.02
1,865.91
2,517.58
3,026.32
3,347.16
growth rate -1.3% -4.6% -1.5% 20.1% 11.7% 42.6% 0.4% 34.9% 20.2% 10.6%
LT Debt 670.30
703.19
527.14
642.35
716.64
814.24
1,180.50
1,086.22
1,610.55
1,822.14
growth rate 4.9% -25.0% 21.9% 11.6% 13.6% 45.0% -8.0% 48.3% 13.1%
Equity 687.40
525.58
600.81
640.98
672.20
733.07
836.77
1,045.08
1,317.33
1,634.58
2,114.60
growth rate -23.5% 14.3% 6.7% 4.9% 9.1% 14.2% 24.9% 26.1% 24.1% 29.4%
Common Shares 63.00
51.00
48.00
48.00
48.00
48.00
48.00
49.00
49.00
50.00
51.00
growth rate -19.1% -5.9% 0.0% 0.0% 0.0% 0.0% 2.1% 0.0% 2.0% 2.0%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 42.86
49.14
47.53
39.15
56.93
63.25
55.29
82.43
140.05
140.51
166.56
growth rate 14.7% -3.3% -17.6% 45.4% 11.1% -12.6% 49.1% 69.9% 0.3% 18.5%
Cash Dividends 0.00 0.00 0.00
growth rate
Cash From OA 169.00
206.84
208.01
209.05
251.05
304.96
314.84
316.27
886.06
1,004.88
1,212.66
growth rate 22.4% 0.6% 0.5% 20.1% 21.5% 3.2% 0.5% 180.2% 13.4% 20.7%
FCF per Share 2.02
3.05
3.31
3.51
3.57
4.67
4.78
4.43
6.60
5.97
8.88
growth rate 51.0% 8.5% 6.0% 1.7% 30.8% 2.4% -7.3% 49.0% -9.6% 48.7%
Sale Purchase of Stock -263.17
-45.83
-72.14
73.69
39.37
23.20
38.87
growth rate 0.0% 0.0% 100.0% -46.6% -41.1% 67.6%
FCF 126.00
156.00
160.00
168.00
194.00
223.00
243.00
234.00
301.00
340.00
380.00
growth rate 23.8% 2.6% 5.0% 15.5% 15.0% 9.0% -3.7% 28.6% 13.0% 11.8%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 1,133.40
1,142.65
1,129.53
1,165.53
1,297.66
1,363.30
1,681.43
1,857.60
2,218.25
2,582.04
2,939.57
growth rate 0.8% -1.2% 3.2% 11.3% 5.1% 23.3% 10.5% 19.4% 16.4% 13.9%
Op.Income -298.50
115.52
102.12
105.42
191.86
230.06
273.13
313.06
331.38
351.15
432.73
growth rate 100.0% -11.6% 3.2% 82.0% 19.9% 18.7% 14.6% 5.9% 6.0% 23.2%
IBT -334.10
132.66
129.75
138.33
177.60
195.43
222.92
296.96
280.84
302.04
446.11
growth rate 100.0% -2.2% 6.6% 28.4% 10.0% 14.1% 33.2% -5.4% 7.6% 47.7%
Net Income -336.70
115.52
102.12
105.42
126.70
149.31
154.77
123.36
226.37
252.02
364.30
growth rate 100.0% -11.6% 3.2% 20.2% 17.9% 3.7% -20.3% 83.5% 11.3% 44.6%
EPS -5.38
2.14
2.01
2.12
2.66
3.13
3.23
2.54
4.62
5.07
7.20
growth rate 100.0% -6.1% 5.5% 25.5% 17.7% 3.2% -21.4% 81.9% 9.7% 42.0%
Gross Profit 384.80
402.24
392.08
394.90
476.00
533.66
658.10
721.87
-47.84
-39.18
2,939.57
growth rate 4.5% -2.5% 0.7% 20.5% 12.1% 23.3% 9.7% -100.0% 0.0% 100.0%

Quarterly Statements

Item Name Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Earnings BIT 94.28
76.77
132.75
128.93
growth rate -18.6% 72.9% -2.9%
Balance Sheet Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Acct.Receivable 542.39
532.53
572.06
610.57
growth rate -1.8% 7.4% 3.3%
Acct.Payable 102.70
82.98
96.76
127.13
growth rate -19.2% 16.6% 14.6%
Cur.Assets 1,208.28
1,234.73
1,140.27
1,201.13
1,423.21
growth rate 2.2% -7.7% 5.3% 18.5%
Total Assets 5,201.79
5,240.88
5,213.34
5,490.83
5,808.96
growth rate 0.8% -0.5% 5.3% 5.8%
Cash 372.43
402.02
242.88
465.41
growth rate 7.9% -39.6% 38.4%
Inventory 162.94
168.37
181.37
185.70
193.58
growth rate 3.3% 7.7% 2.4% 4.3%
Cur.Liabilities 690.90
727.94
787.01
839.75
803.38
growth rate 5.4% 8.1% 6.7% -4.3%
Liabilities 3,522.12
3,460.28
3,287.84
3,347.16
3,592.74
growth rate -1.8% -5.0% 1.8% 7.3%
LT Debt 2,300.89
growth rate
Equity 1,651.98
1,752.64
1,896.94
2,114.60
2,183.93
growth rate 6.1% 8.2% 11.5% 3.3%
Common Shares 49.49
49.66
49.74
49.77
50.22
growth rate 0.4% 0.2% 0.1% 0.9%
Cash Flow Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Capital Expenditures 25.72
26.80
26.19
87.85
growth rate 4.2% -2.3% 235.5%
Cash Dividends
growth rate
Cash From OA 68.59
162.31
177.30
804.46
growth rate 136.6% 9.2% 353.7%
Sale Purchase of Stock
growth rate
FCF 42.87
135.51
151.12
716.61
growth rate 216.1% 11.5% 374.2%
Income Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Sales 680.54
663.42
745.22
826.47
growth rate -2.5% 12.3% 10.9%
Op.Income 94.28
76.77
132.75
128.93
growth rate -18.6% 72.9% -2.9%
IBT 55.39
83.72
135.57
171.43
growth rate 51.1% 61.9% 26.5%
Net Income 50.77
67.44
102.91
143.19
growth rate 32.8% 52.6% 39.1%
EPS
growth rate
Gross Profit -26.52
663.42
745.22
299.97
growth rate 100.0% 12.3% -59.8%
R&D
growth rate

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A+ (94.59)

YOY Growth Grade:

B (68.36)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 47.58 44.06 32.16
EPS / Growth 15.4% 7.20 13.2%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 21.8%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 13.2% 16.8% 16.8%
Future PE 26.46 37.77 37.77
Future EPS 24.94 33.99 33.99
Value Price
MOS %
163.14
-48.6%
317.40
0.1%
317.40
0.1%
MOS Price 81.57 158.70 158.70
IRT 14.60 12.83 12.83

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.